GGrantIndex
← Leaderboards

Alexander I. Agoulnik

Baylor College Of Medicine

$7,344,882
Attributed
$7,762,536
Total exposure
10
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $761.6K · FY200524
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$7,762,536 · 10

By mechanism

R01$5,209,383 · 3
R21$1,106,467 · 3
U01$585,716 · 1
P01$527,262 · 1
R41$308,708 · 1
R03$25,000 · 1

Top collaborators

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Signal Transduction

Research focus

Signal TransductionResponseG-Protein-Coupled ReceptorsReceptorRelaxinIn VivoMaleDesignSeriesAgonistFutureRelaxin ReceptorLaboratoriesBasePeptidesAnimal ModelSmall MoleculeCryptorchidismProductionGene ExpressionIn VitroPhenotypeAffectExtracellular Matrix

Grant awards (31)

Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor$199,856
R21 · FY2024 · CA
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor$172,391
R21 · FY2023 · CA
Relaxin receptor agonists for treatment of liver fibrosis$326,152
R01 · FY2021 · DK · contact PI
Engineering a long-acting relaxin agonist to treat liver fibrosis$308,708
R41 · FY2021 · DK
Relaxin receptor agonists for treatment of liver fibrosis$333,955
R01 · FY2020 · DK · contact PI
Relaxin receptor agonists for treatment of liver fibrosis$437,423
R01 · FY2019 · DK · contact PI
Relaxin receptor agonists for treatment of liver fibrosis$434,786
R01 · FY2018 · DK · contact PI
Small molecule agonists of insulin-like3 receptor for treatment of osteoporosis$315,019
R01 · FY2018 · AR · contact PI
Relaxin receptor agonists for treatment of liver fibrosis$446,411
R01 · FY2017 · DK · contact PI
Small molecule agonists of insulin-like3 receptor for treatment of osteoporosis$315,208
R01 · FY2017 · AR · contact PI
Small molecule agonists of insulin-like3 receptor for treatment of osteoporosis$255,200
R01 · FY2016 · AR · contact PI
Small molecule antagonists of relaxin receptor$288,313
U01 · FY2014 · CA · contact PI
Small molecule antagonists of relaxin receptor$297,403
U01 · FY2013 · CA · contact PI
Role of Y chromosomal genes in male fertility$175,725
R21 · FY2010 · HD · contact PI
Role of Y chromosomal genes in male fertility$228,495
R21 · FY2009 · HD · contact PI
Small molecule agonists of the relaxin receptor$25,000
R03 · FY2009 · MH · contact PI
Genetic basis of testicular descent$311,645
R01 · FY2008 · HD · contact PI
Targeting Relaxin Signaling in Prostate Cancer$150,000
R21 · FY2008 · CA · contact PI
Genetic basis of testicular descent$86
R01 · FY2008 · HD · contact PI
Genetic basis of testicular descent$321,078
R01 · FY2007 · HD · contact PI
Targeting Relaxin Signaling in Prostate Cancer$180,000
R21 · FY2007 · CA · contact PI
Genetic basis of testicular descent$330,668
R01 · FY2006 · HD · contact PI
Genetic basis of testicular descent$338,625
R01 · FY2005 · HD
Genetic basis of testicular descent$338,625
R01 · FY2004 · HD
GENETIC CONTROL OF EARLY TESTICULAR DESCENT$176,108
R01 · FY2003 · HD
GENETIC CONTROL OF EARLY TESTICULAR DESCENT$175,754
P01 · FY2002 · HD
GENETIC CONTROL OF EARLY TESTICULAR DESCENT$170,976
R01 · FY2002 · HD
GENETIC CONTROL OF EARLY TESTICULAR DESCENT$175,754
P01 · FY2001 · HD
GENETIC CONTROL OF EARLY TESTICULAR DESCENT$165,997
R01 · FY2001 · HD
GENETIC CONTROL OF EARLY TESTICULAR DESCENT$191,421
R01 · FY2000 · HD
GENETIC CONTROL OF EARLY TESTICULAR DESCENT$175,754
P01 · FY2000 · HD